Establishment Labs (ESTA) to Release Earnings on Wednesday

05 May 2026, 05:53 by Renee Jackson · The Cerbat Gem

Establishment Labs (NASDAQ:ESTA – Get Free Report) is anticipated to post its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect Establishment Labs to post earnings of ($0.3550) per share and revenue of $57.4470 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 8:30 AM ET.

Establishment Labs (NASDAQ:ESTA – Get Free Report) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.13. The business had revenue of $64.62 million for the quarter, compared to analyst estimates of $63.80 million. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. The company’s revenue for the quarter was up 45.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.19) earnings per share. On average, analysts expect Establishment Labs to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Establishment Labs Stock Up 0.0%

ESTA opened at $70.24 on Tuesday. Establishment Labs has a twelve month low of $32.25 and a twelve month high of $83.31. The company’s 50-day moving average price is $65.53 and its two-hundred day moving average price is $66.03. The stock has a market cap of $2.06 billion, a price-to-earnings ratio of -40.37 and a beta of 1.12. The company has a quick ratio of 2.00, a current ratio of 3.04 and a debt-to-equity ratio of 10.51.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on ESTA shares. Wall Street Zen cut shares of Establishment Labs from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. BTIG Research reissued a “buy” rating and issued a $88.00 target price on shares of Establishment Labs in a research report on Wednesday, April 29th. Mizuho boosted their target price on Establishment Labs from $90.00 to $100.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a research report on Friday, March 27th. Finally, Stephens increased their price target on Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $86.86.

View Our Latest Research Report on Establishment Labs

Insider Activity

In other Establishment Labs news, Director Quiros Juan Jose Chacon sold 7,751 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $70.48, for a total transaction of $546,290.48. Following the sale, the director owned 1,032,504 shares in the company, valued at $72,770,881.92. This represents a 0.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 225,000 shares of company stock worth $14,935,438 in the last quarter. Corporate insiders own 9.99% of the company’s stock.

Institutional Trading of Establishment Labs

Institutional investors have recently added to or reduced their stakes in the stock. Nantahala Capital Management LLC boosted its stake in Establishment Labs by 11.1% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,973,492 shares of the company’s stock worth $80,893,000 after purchasing an additional 197,962 shares during the period. Bamco Inc. NY increased its position in shares of Establishment Labs by 21.5% during the second quarter. Bamco Inc. NY now owns 907,537 shares of the company’s stock valued at $38,761,000 after buying an additional 160,755 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Establishment Labs by 117.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock valued at $59,145,000 after buying an additional 438,206 shares during the period. Mudita Advisors LLP lifted its holdings in shares of Establishment Labs by 1.9% in the fourth quarter. Mudita Advisors LLP now owns 699,703 shares of the company’s stock worth $50,994,000 after buying an additional 12,939 shares in the last quarter. Finally, Balyasny Asset Management L.P. lifted its holdings in shares of Establishment Labs by 50.9% in the second quarter. Balyasny Asset Management L.P. now owns 488,688 shares of the company’s stock worth $20,872,000 after buying an additional 164,788 shares in the last quarter. Hedge funds and other institutional investors own 72.91% of the company’s stock.

About Establishment Labs

(Get Free Report)

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.